| Old Articles: <Older 5691-5700 Newer> |
|---|
 |
The Motley Fool
June 12, 2009
Brian Orelli |
Be Careful What You Wish For Do you have the stomach to profit from swine flu?   |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
BusinessWeek
June 11, 2009
Kerry Capell |
Novartis: Radically Remaking Its Drug Business CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials. |
BusinessWeek
June 10, 2009
Arlene Weintraub |
The Fight Over Drug Data Mining Prescription-data collector IMS's legal drama unfolds in a battle over privacy and free speech, and could be headed to the Supreme Court |
BusinessWeek
June 9, 2009
John Carey |
Giving Patients the Data They Need A growing effort by doctors, insurers, and politicians helps people make better-informed medical decisions |
The Motley Fool
June 11, 2009
Brian Orelli |
The FTC Hates You, Too The agency weighs in (unhappily) on follow-on biologics. |
The Motley Fool
June 11, 2009
Brian Orelli |
Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children. |
The Motley Fool
June 10, 2009
Brian Orelli |
Up 58% on No News? What's Going On? There's no concrete reason for the massive increase in Sequenom yesterday. The stock was flat until noon, then it steadily climbed up to the moon in afternoon trading. |
The Motley Fool
June 9, 2009
Brian Orelli |
Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out. |
Inc.
June 2009
Nicole Marie Richardson |
Innovation: CardioMEMS EndoSure Sensor CardioMEMS creates body sensors that monitor cardiovascular health. |
| <Older 5691-5700 Newer> Return to current articles. |
